Anti-influenza drugs and neuraminidase inhibitors

2001 ◽  
pp. 35-77
Author(s):  
Noel A. Roberts
Keyword(s):  
Neuraminidase Inhibitors

Neuraminidase Inhibitors fromReynoutria elliptica

2003 ◽  
Vol 26 (5) ◽  
pp. 367-374 ◽  
Author(s):  
Chu-Hyun Lee ◽  
Sang-ln Kim ◽  
Kyung-Bok Lee ◽  
Yung-Choon Yoo ◽  
Si-Young Ryu ◽  
...  
Keyword(s):  
Neuraminidase Inhibitors

scholarly journals Structure-based design of 5′-substituted 1,2,3-triazolylated oseltamivir derivatives as potent influenza neuraminidase inhibitors

RSC Advances ◽  
2021 ◽  
Vol 11 (16) ◽  
pp. 9528-9541 ◽  
Author(s):  
Pengfei Wang ◽  
Babayemi O. Oladejo ◽  
Chenning Li ◽  
Lifeng Fu ◽  
Shanshan Zhang ◽  
...  
Keyword(s):  
Neuraminidase Inhibitors ◽  
Charged Residues

Exploring influenza neuraminidase inhibitors by targeting the charged residues near the entrance of the 150-cavity.

A new series of C3-aza carbocyclic influenza neuraminidase inhibitors: synthesis and inhibitory activity

1998 ◽  
Vol 8 (23) ◽  
pp. 3321-3324 ◽  
Author(s):  
Willard Lew ◽  
Huiwei Wu ◽  
Dirk B. Mendel ◽  
Paul A. Escarpe ◽  
Xiaowu Chen ◽  
...  
Keyword(s):  
Inhibitory Activity ◽  
Neuraminidase Inhibitors

scholarly journals Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients

2015 ◽  
Vol 45 (6) ◽  
pp. 1642-1652 ◽  
Author(s):  
Nelson Lee ◽  
Yee-Sin Leo ◽  
Bin Cao ◽  
Paul K.S. Chan ◽  
W.M. Kyaw ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Cox Regression ◽  
Management Strategies ◽  
Patient Characteristics ◽  
Primary Outcome Measure ◽  
Time Dependent ◽  
High Morbidity ◽  
Neuraminidase Inhibitors ◽  
Systemic Corticosteroids ◽  
Time Dependent Analysis

We aimed to study factors influencing outcomes of adults hospitalised for seasonal and pandemic influenza. Individual-patient data from three Asian cohorts (Hong Kong, Singapore and Beijing; N=2649) were analysed. Adults hospitalised for laboratory-confirmed influenza (prospectively diagnosed) during 2008–2011 were studied. The primary outcome measure was 30-day survival. Multivariate Cox regression models (time-fixed and time-dependent) were used.Patients had high morbidity (respiratory/nonrespiratory complications in 68.4%, respiratory failure in 48.6%, pneumonia in 40.8% and bacterial superinfections in 10.8%) and mortality (5.9% at 30 days and 6.9% at 60 days). 75.2% received neuraminidase inhibitors (NAI) (73.8% received oseltamivir and 1.4% received peramivir/zanamivir; 44.5% of patients received NAI ≤2 days and 65.5% ≤5 days after onset of illness); 23.1% received systemic corticosteroids. There were fewer deaths among NAI-treated patients (5.3% versus 7.6%; p=0.032). NAI treatment was independently associated with survival (adjusted hazard ratio (HR) 0.28, 95% CI 0.19–0.43), adjusted for treatment-propensity score and patient characteristics. Superinfections increased (adjusted HR 2.18, 95% CI 1.52–3.11) and chronic statin use decreased (adjusted HR 0.44, 95% CI 0.23–0.84) death risks. Best survival was shown when treatment started within ≤2 days (adjusted HR 0.20, 95% CI 0.12–0.32), but there was benefit with treatment within 3–5 days (adjusted HR 0.35, 95% CI 0.21–0.58). Time-dependent analysis showed consistent results of NAI treatment (adjusted HR 0.39, 95% CI 0.27–0.57). Corticosteroids increased superinfection (9.7% versus 2.7%) and deaths when controlled for indications (adjusted HR 1.73, 95% CI 1.14–2.62). Early NAI treatment was associated with shorter length of stay in a subanalysis.NAI treatment may improve survival of hospitalised influenza patients; benefit is greatest from, but not limited to, treatment started within 2 days of illness. Superinfections and corticosteroids increase mortality. Antiviral and non-antiviral management strategies should be considered.

scholarly journals In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses

2008 ◽  
Vol 79 (3) ◽  
pp. 199-205 ◽  
Author(s):  
Ching-Yao Su ◽  
Shi-Yun Wang ◽  
Jiun-Jie Shie ◽  
King-Song Jeng ◽  
Nigel J. Temperton ◽  
...  
Keyword(s):  
Neuraminidase Inhibitors ◽  
In Vitro Evaluation ◽  
Release Assay

Combination of Neuraminidase Inhibitors with T-705 for Treating Influenza Virus Infections in Cell Culture and in Mice

2009 ◽  
Vol 82 (2) ◽  
pp. A37
Author(s):  
Donald Smee ◽  
Min-Hui Wong ◽  
Kevin Bailey ◽  
John Morrey ◽  
Masako Maekawa ◽  
...  
Keyword(s):  
Cell Culture ◽  
Influenza Virus ◽  
Neuraminidase Inhibitors ◽  
Virus Infections

Neuraminidase inhibitors as antivirals

Vaccine ◽  
2002 ◽  
Vol 20 ◽  
pp. S55-S58 ◽  
Author(s):  
P.M Colman
Keyword(s):  
Neuraminidase Inhibitors

Accumulation of segment 6 sgRNAs of influenza A viruses in the presence of neuraminidase inhibitors

2001 ◽  
Vol 1219 ◽  
pp. 845-853 ◽  
Author(s):  
Marina S Nedyalkova ◽  
Frederick G Hayden ◽  
Robert G Webster ◽  
Larisa V Gubareva
Keyword(s):  
Influenza A ◽  
Neuraminidase Inhibitors ◽  
Influenza A Viruses
Sign in / Sign up

Export Citation Format

Share Document